Bernard Mental Health Impact Bernard Mental Health Impact Harold and Friends learn about how living with multiple health conditions can impact mental health
World-Psoriasis-Day-IFPA-Interview World-Psoriasis-Day-IFPA-Interview Interview with the International Federation of Psoriasis Associations (IFPA)
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
2024 half year results innovation progress 2024 half year results innovation progress First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021 Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Acquisition Saint-Herblon site and Coophavet brand Acquisition Saint-Herblon site and Coophavet brand Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
History video History video Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Lung Repair & Regeneration Video Lung Repair & Regeneration Video Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Sore Mouth or Throat Sore Mouth or Throat Discover tips on how to take care of a sore mouth or throat from Taking Cancer On Through Flavour
Veganism Veganism Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Roasted Eggplant Fan Video Roasted Eggplant Fan Video Find out how this simple plant-based meal from Taking Cancer on Through Flavour and Taste Life are made
Ivan Blanarik Therapeutic Area Head Respiratory Ivan Blanarik Therapeutic Area Head Respiratory Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Four Pillars Cancer Immunology Four Pillars Cancer Immunology Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
CHMP_opinion_Nintedanib_SSc-ILD CHMP_opinion_Nintedanib_SSc-ILD Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
European_Commission_approves_nintedanibSSc-ILD European_Commission_approves_nintedanibSSc-ILD Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Partnership-with-clicktherapeutics Partnership-with-clicktherapeutics Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.